In just four months, Abbott has achieved three key milestones for its sensor-based glucose monitoring tech: FreeStyle Libre 2 was cleared in June by the U.S.
![skins para freestyle dash 3 skins para freestyle dash 3](https://3.bp.blogspot.com/-XNY5mx_s6jI/WF5qbsFssuI/AAAAAAAAN6g/WEP_QLn2CWQx7NVLnlzpwUJ4pS5vSf1cQCLcB/s1600/Rapido%2By%2Bfurioso%2B7.png)
Affordable 6 - To allow as many people as possible living with diabetes to access and benefit from the tech, Abbott's FreeStyle Libre 3 system will be priced the same as previous generations of the device, which is a third of the cost of other CGMs available.
![skins para freestyle dash 3 skins para freestyle dash 3](https://i.ytimg.com/vi/6QqJNG84rAg/maxresdefault.jpg)
![skins para freestyle dash 3 skins para freestyle dash 3](https://k41.kn3.net/C/A/8/D/D/C/A9F.jpg)
Abbott has kept a steady drumbeat of innovation across its FreeStyle portfolio in 2020 and the company isn’t about to break its streak now.